Tango Therapeutics reports Q1 EPS (32c), consensus (31c)

Reports Q1 revenue $0 vs. $5.4M last year “We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer and remain highly encouraged by the potential of the ongoing study of vopimetostat in combination with RAS(ON) inhibitors,” said Malte Peters, CEO. “With a recently strengthened leadership team intended to support the late-stage advancement of vopimetostat, we are focused on the clinical and regulatory work required to initiate a pivotal study in MTAP-deleted pancreatic cancer. We remain committed to evaluating the potential of our broader pipeline, with key inflection points remaining this year, including monotherapy vopimetostat data in lung cancer and initial TNG456 data in glioblastoma.”